The DOI matches its Crossref record.
Arachidonic acid metabolism in purified human lung mast cells.
Abstract
Arachidonic acid metabolism has been explored in preparations of purified human lung mast cells prelabeled with arachidonic acid (AA). Cells were of 83 to greater than 96% purity, and each experiment was performed with four to six different preparations of mast cells. After overnight culture of the purified cells in the presence of 3H-AA, followed by extensive washing in buffer, mast cell uptake of labeled AA was 61.4 +/- 14.8 pmol/10(6) cells with 21 +/- 2.4% of the label in phospholipids, 73 +/- 2.1% in neutral lipids, and 3.6 +/- 0.8% as free AA. Analysis of the distribution of radioactivity in phospholipid classes revealed 51.4 +/- 5.5% of the label in phosphatidylcholine, 14.5 +/- 1.6% in phosphatidylinositol, 12.0 +/- 3.0% in phosphatidylethanolamine, and 9.1 +/- 2.4% in sphingomyelin, with the rest in other phospholipid classes. Challenge of these cells with an optimal concentration of anti-IgE led to the release of 20 +/- 4.0% of cellular histamine and to a reduction in labeled phosphatidylcholine and phosphatidylinositol to 75.5 +/- 8.8% and 84.2 +/- 4.5% of the control levels, respectively, (p less than 0.05); anti-IgE challenge produced no statistically significant change in the quantities of other labeled phospholipids. Activation of human lung mast cells with anti-IgE led to the release of 3.4 +/- 1.3% of the cellular 3H as AA and AA metabolites (1.5 +/- 0.6% as unmetabolized AA) in conjunction with 16 +/- 4.3% of the cellular histamine. Although activation of human lung mast cells with ionophore A23187 caused 70 +/- 1.1% histamine release, a similar quantity of AA and AA metabolites was released (a total of 4.0 +/- 0.8% with 2.3 +/- 1.5% as unmetabolized AA). Analysis of the released metabolites by liquid scintillation spectrometry after high performance liquid chromatography separation showed that approximately equal amounts of metabolites were produced after mast cell activation with anti-IgE and ionophore A23187. In this series of experiments approximately equal amounts of cyclooxygenase and lipoxygenase products were generated.The distribution of metabolites (as a percentage of total metabolites) after activation with anti-IgE and A23187 were as follows: prostaglandin D2, 56 +/- 6.4%, 51 +/- 12% (anti-IgE and A23187, respectively); leukotriene C, 21 +/- 5.2%, 17 +/- 4.1%; leukotriene B isomers 16 +/- 3.1%, 12 +/- 0.5%; an unknown product 5.8 +/- 1.5%, 7.1 +/- 2.8%; and 5HETE 2.3 +/- 2.1%, 13 +/- 8.1%. We conclude that activation of purified preparations of human lung mast cells with anti-IgE leads to phospholipid turnover (phosphatidylcholine and phosphatidylinosi-tol), and to the release of AA metabolites from both the cyclooxygenase (prostaglandin D2) and lipoxygenase (leukotriene C, leukotriene B isomers, and 5HETE) pathways. Although challenge with anti-IgE and ionophore A23187 resulted in histamine release that was markedly different, the two stimuli led to the release of similar quantities and types of AA metabolites. The procedures described here should be useful in exploring biochemical and pharmacologic aspects of AA metabolism in purified human lung mast cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Two types of human mast cells that have distinct neutral protease compositions.
Irani, A. A., Schechter, N. M., Craig, S. S., DeBlois, G., & Schwartz, L. B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4464 · Cited by 1,005
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Establishment of an immature mast cell line from a patient with mast cell leukemia
Butterfield, J. H., Weiler, D., Dewald, G., & Gleich, G. J. (1988) · Leukemia Research · doi:10.1016/0145-2126(88)90050-1 · Cited by 737
Mast Cell Function: A New Vision of an Old Cell
da Silva, E. Z. M., Jamur, M. C., & Oliver, C. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414545334 · Cited by 604
Galli, S. J. (2000) · Current Opinion in Hematology · doi:10.1097/00062752-200001000-00007 · Cited by 521
Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to Ragweed
Creticos, P. S., Peters, S. P., Adkinson, N. F., Naclerio, R. M., Hayes, E. C., Norman, P. S., & Lichtenstein, L. M. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406213102502 · Cited by 394
Self-citationReduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production
Broughton, K., Johnson, C., Pace, B., Liebman, M., & Kleppinger, K. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.4.1011 · Cited by 270
Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation
Boyce, J. A. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00512.x · Cited by 254
Shimura, C., Satoh, T., Igawa, K., Aritake, K., Urade, Y., Nakamura, M., & Yokozeki, H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090111 · Cited by 60
Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
Butterfield, J., & Weiler, C. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.021 · Cited by 41
Metadata
- Authors
- Peters, S. P., MacGlashan, D. W., Schulman, E. S., Schleimer, R. P., Hayes, E. C., Rokach, J., Adkinson, N. F., & Lichtenstein, L. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1984-04-01
- Volume
- 132
- Issue
- 4
- Pages
- 1972-1979
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1922797677
- Cited by
- 235
- References
- 0
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.